Clinical trials: Lipid Disorders
Heart Diseases, Diabetes Mellitus, Type 2
Behavior Change Intervention for Cardiovascular Risk Reduction Among People Experiencing Homelessness
This single-arm trial of the Cardiovascular Risk Reduction Among People Experiencing Homelessness (CV-Homes) intervention alone (n=8) will test the perception and feasibility of anticipated study procedures.
- Conditions
- Heart Diseases, Diabetes Mellitus, Type 2, Pre-diabetes, Hypertension
- Trial name
- CV-Homes (NCT06025721)
- Testing
- Cardiovascular Risk Homeless Support
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Katherine Vickery
Niemann-Pick Disease, Type C1
Combined Intrathecal and Intravenous VTS-270 Therapy for Liver and Neurological Disease Associated With Niemann-Pick Disease, Type C1
Background: For people who have Niemann-Pick disease, type C1 (NPC1), cholesterol and other fats have trouble moving out of liver and other tissue cells. This makes the cells sick.
- Trial name
- NCT03887533
- Testing
- VTS-270
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Abdominal Obesity, Insulin Resistance
Effects of Acipimox on Mitochondrial Function in Obesity
The purpose of the study is to examine whether a medication called acipimox can improve your body's mitochondria. Mitochondria are the "power house" of the cell and make energy for your body.
- Conditions
- Abdominal Obesity, Insulin Resistance, Hypertriglyceridemia
- Trial name
- NCT01488409
- Testing
- Acipimox
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Massachusetts General Hospital
Homozygous Familial Hypercholesterolemia
Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
The primary objective of the study is to demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) with alirocumab subcutaneous (SC) every 2 weeks (Q2W) in comparison to placebo after 12 weeks of treatment.
- Trial name
- ODYSSEY HoFH (NCT03156621)
- Testing
- Alirocumab
- Where
- 28 sites in United States, Austria and 11 more
- Volunteers
- 69 people
- Sponsor
- Regeneron Pharmaceuticals
Ametropia
Evaluation of Disinfecting Solutions and Protein Remover With a Silicone Hydrogel Lens
The purpose of this study is to determine if reduced lens deposits and increased comfort can be achieved by using Multipurpose disinfecting solutions (MPDS) in a no-rub format but in conjunction with an intensive cleaner, rather…
- Trial name
- NCT00754338
- Testing
- Alcon Opti-Free® RepleniSH® with Supraclens®, Alcon Opti-Free® RepleniSH®, B&L ReNu MultiPlus™
- Where
- Canada
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- University of Waterloo
Fabry Disease, Alpha Galactosidase A Deficiency
Study of the Effects of Fabrazyme Treatment on Lactation and Infants
The study was planned for up to 2 years (24 months). Planned full participation for both mother and infant was 24 months, planned full participation of mother and development of infant was 24 months, while planned full…
- Trial name
- NCT00230607
- Testing
- agalsidase beta
- Where
- 5 sites in United States, Austria and 1 more
- Volunteers
- 7 people
- Sponsor
- Genzyme, a Sanofi Company
Body Fat Disorder
Submental Study (Sequential Treatment Approach)
Evaluate the safety and efficacy of subcutaneous fat layer reduction in the submental area using multiple therapeutic tools.
- Trial name
- CMK (NCT03510598)
- Testing
- The ZELTIQ CoolSculpting System, Kybella 20 MG in 2 ML Injection
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Zeltiq Aesthetics
Cardiovascular Diseases, Heart Diseases
Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia
This study will evaluate the efficacy of diet and exercise (DE), with and without niacin and fenofibrate, in reducing the cardiovascular risk of patients with HIV lipodystrophy or dyslipidemia.
- Conditions
- Cardiovascular Diseases, Heart Diseases, HIV Infections, Hyperlipidemia
- Trial name
- HeartPositive (NCT00246376)
- Testing
- Diet, Exercise, Niacin
- Where
- United States
- Volunteers
- 221 people
- Sponsor
- Baylor College of Medicine
Hepatocellular Carcinoma
Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma
The purpose of this study is to assess the safety and tolerability of the investigational anticancer drug DCR-MYC. DCR-MYC is a novel synthetic double-stranded RNA in a stable lipid particle suspension that targets the oncogene…
- Trial name
- NCT02314052
- Testing
- DCR-MYC
- Where
- 6 sites in United States, Singapore and 1 more
- Volunteers
- 21 people
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Fabry Disease, Lysosomal Storage Diseases
A Fabry Disease Gene Therapy Study
This is a multinational, open-label study to assess the safety and efficacy of FLT190 in up to 15 adult male participants with classical Fabry disease.
- Trial name
- MARVEL1 (NCT04040049)
- Testing
- FLT190
- Where
- 13 sites in United States, Austria and 5 more
- Volunteers
- 3 people
- Sponsor
- Spur Therapeutics
HIV Infection, Hyperlipidemia
Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study
The purpose of this study is to evaluate the change in brachial artery reactivity in HIV-infected subjects with elevated lipid levels who are switched to an atazanavir containing antiretroviral regimen
- Trial name
- SABAR (NCT00225017)
- Testing
- Atazanavir, current antiretroviral regimen
- Where
- 7 sites in United States, Argentina and 1 more
- Volunteers
- 50 people
- Sponsor
- Northwestern University
Juvenile Neuronal Ceroid Lipofuscinosis
Cellcept for Treatment of Juvenile Neuronal Ceroid Lipofuscinosis
The primary objective of this trial is to establish the safety and tolerability of short-term (8 weeks) administration of mycophenolate mofetil in ambulatory children with JNCL.
- Trial name
- JUMP (NCT01399047)
- Testing
- Mycophenolate mofetil
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Rochester
Mucopolysaccharidosis, Hurler Syndrome
Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders
Rationale: Chemotherapy administration before a donor stem cell transplant is necessary to stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Mucopolysaccharidosis, Hurler Syndrome, Hunter Syndrome, Maroteaux-Lamy Syndrome
- Trial name
- NCT01043640
- Testing
- Campath-1H, Cyclophosphamide, Busulfan
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Body Fat Disorder
Pilot Study on the Submental Area
The purpose of this study is to evaluate the safety and feasibility of cryolipolysis for non-invasive reduction of submental fat.
- Trial name
- NCT01859091
- Testing
- The Zeltiq System
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Zeltiq Aesthetics
Dyslipidemia
Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries
This is a multicenter, open-label extension (OLE) study designed to assess the extended long-term safety of evolocumab in subjects who have completed the FOURIER trial (Study 20110118).
- Trial name
- NCT03080935
- Testing
- Evolocumab
- Where
- 85 sites in Belgium, Denmark and 5 more
- Volunteers
- 1,600 people
- Sponsor
- Amgen
Hyperlipidemias, Hypertension
The Effect of Farlong® NotoGinseng™ (Ginseng Plus®) on Cholesterol and Blood Pressure
In this randomized, placebo-controlled, double-blind parallel study in human participants with elevated LDL-C and elevated BP described here, the clinical benefits of Farlong NotoGinseng™ (Farlong Ginseng Plus® Panax Notoginseng…
- Trial name
- NCT04069715
- Testing
- Farlong NotoGinseng™ (Farlong Ginseng Plus® Panax Notoginseng extract)
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- LongStar HealthPro, Inc. DBA Farlong Pharmaceutical
Hypercholesterolemia
A Patient-Spouse Intervention for Self-Managing High Cholesterol
We examined the effect of a patient-spouse intervention to lower LDL-C by increasing patient treatment adherence. A randomized controlled trial compared a one-year, telephone-based patient-spouse intervention to usual care.
- Trial name
- CouPLES (NCT00321789)
- Testing
- spouse-assisted intervention
- Where
- United States
- Volunteers
- 255 people, healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Diabetes Mellitus
Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus
The purpose of the study is to compare the effect of adding alogliptin, once daily (QD), to the ongoing treatment regimen of pioglitazone HCl and metformin in patients with inadequate glycemic control.
- Trial name
- NCT00432276
- Testing
- Alogliptin, Pioglitazone, Metformin
- Where
- 86 sites in United States
- Volunteers
- 803 people
- Sponsor
- Takeda
Cardiovascular Disease
Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study
Evaluate the effect of olpasiran administered subcutaneously (SC) compared with placebo, on percent change from baseline in lipoprotein(a) (Lp[a]).
- Trial name
- NCT04270760
- Testing
- Olpasiran
- Where
- 36 sites in United States, Australia and 5 more
- Volunteers
- 281 people
- Sponsor
- Amgen
Metabolic Syndrome X, Overweight
Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)
Metabolic syndrome consists of a group of co-occuring conditions that increase an individual's risk of developing heart disease, stroke, and diabetes.
- Conditions
- Metabolic Syndrome X, Overweight, Hypertension, Dyslipidemias
- Trial name
- ARCH-MS (NCT00455325)
- Testing
- Active Comparator: Second Intervention (3 weeks), Active Comparator: Third Intervention (3 weeks), Active Comparator: Fourth Intervention (3 weeks)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Washington University School of Medicine